Sunosi-150 mg

Sunosi-150 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Sunosi-150 mg marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Sunosi-150 mg was given FDA approval in 2019.

Sunosi-150 mg weakly binds to dopamine and norepinephrine transporters but not serotonin transporters. Sunosi-150 mg does not bind to dopamine, serotonin, norepinephrine, GABA, adenosine, histamine, orexin, benzodiazepines, or muscarinic and nicotinic receptors.

Sunosi-150 mg is also associated with a mean increase of 21 beats per minute (BPM) in heart rate in patients taking 300mg (twice the maximum recommended dose) and 27 BPM in patients taking 900mg (six times the maximum recommended dose). 300mg of solriamfetol does not increase the QTcF interval to a clinically relevant degree.

Trade Name Sunosi-150 mg
Availability Prescription only
Generic Solriamfetol
Solriamfetol Other Names Solriamfetol
Related Drugs Adderall, methylphenidate, Concerta, modafinil, Ritalin, dextroamphetamine, armodafinil, Provigil, Nuvigil, Sunosi
Type
Formula C10H14N2O2
Weight Average: 194.234
Monoisotopic: 194.105527699
Protein binding

13.3% to 19.4% protein bound over a plasma concentration range of 0.059 to 10.1mcg/mL.

Groups Approved
Therapeutic Class
Manufacturer Jazz Pharmaceuticals UK
Available Country United Kingdom
Last Updated: September 19, 2023 at 7:00 am
Sunosi-150 mg
Sunosi-150 mg

Uses

Sunosi-150 mg is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy, but is not a treatment for the underlying airway obstruction in apnea patients.

Sunosi-150 mg is also used to associated treatment for these conditions: Daytime Sleepiness

How Sunosi-150 mg works

The specific mechanism of action is unknown but it may be through its activity as a dopamine and norepinephrine reuptake inhibitor.

Toxicity

Age, gender, and race do not significantly affect solriamfetol pharmacokinetics and no dose adjustments were made in clinical trials for patients over 65 years.

Patients with renal failure experience increases in half life between 1.2 and 3.9 times that in healthy patients. 21% of solriamfetol was removed by hemodialysis, however time to peak concentration was not affected.

Sunosi-150 mg is not expected to lead to adverse effects in pregnancy. Maternal and fetal toxicity was seen in animal studies at ≥4 and 5 times the maximum recommended human dose and teratogenicity was seen at 19 and ≥5 times the maximum recommended human dose.

Breastfed infants should be monitored for adverse reactions such as agitation, insomnia, anorexia, and reduced weight gain as solriamfetol is present in breast milk. However, there is no currently available data on the effect of solriamfetol in breast milk on breast fed inants.

Safety and effectiveness of solriamfetol in pediatric patients has not been established in clinical studies.

Sunosi-150 mg does not display different safety or effectiveness in geriatric populations.

Dosage adjustments are recommended for patients with eGFR Label.

Food Interaction

  • Take with or without food.

Volume of Distribution

199L. Other studies have found the volume of distribution to be 158.2L ± 37.3L in fasted subjects and 159.8L ± 38.9L in fed subjects.

Elimination Route

Oral bioavailability of solriamfetol is approximately 95%. Peak plasma concentration is reached in 2 hours (with a range of 1.25 to 3 hours) in fasted patients. When solriamfetol is taken with a high fat meal, the time to peak plasma concentration increases to 3 hours.

Half Life

7.1 hours. Other studies have found the mean half life to be 6.1 ± 1.2 hours in fasted subjects and 5.9 ± 1.2 hours in fed subjects.

Clearance

Renal clearance is 18.2L/h and total clearance is 19.5L/h. Other studies have found clearance to be 18.4 ± 4.2L/h in fasted subjects and 18.8 ± 4.2L/h in fed subjects.

Elimination Route

95% of solriamfetol is recovered in urine unchanged by metabolism. Less than 1% of solriamfetol is recovered as N-acetyl solriamfetol.

Innovators Monograph

You find simplified version here Sunosi-150 mg

*** Taking medicines without doctor's advice can cause long-term problems.
Share